These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
Researchers involved in the OPTIMISTIC trial have published a scientific paper that identifies genetic factors that influence the severity of myotonic dystrophy type 1.Read more
Audentes Therapeutics has provided an update on its drugs in development for myotubular myopathy, Duchenne muscular dystrophy, myotonic dystrophy type 1 and Pompe disease.
Our Research Communications Manager, Dr Jenny Sharpe, recently attended the twelfth meeting of the International Myotonic Dystrophy Consortium (IDMC) in Gothenburg, Sweden.
The first set of care recommendations for congenital and childhood-onset myotonic dystrophy type 1, and myotonic dystrophy type 2 have been published.
As part of the IMI PREFER project, we’re working with Newcastle University to conduct focus groups for people with myotonic dystrophy type 1 or mitochondrial disease.
A landmark trial has shown that cognitive behavioural therapy (CBT) can benefit people with myotonic dystrophy type 1.
A £35,000 investment into myotonic dystrophy at St Andrews University will ‘bring hope’ to those living with it, says Diana, Countess of Lindsay.
A new research study using data from the UK myotonic dystrophy patient registry has been published. The registry is funded by MDUK and the MDSG.
The conference included talks and posters on a range of neuromuscular conditions. We were delighted to see lots of MDUK-funded researchers in attendance.
AMO Pharma recently presented data from its trial investigating a drug called tideglusib.
A new version of CRISPR/Cas9 has been used to remove the toxic RNA that causes myotonic dystrophy.